ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1377

Prevalence of Spondyloarthritis-Related Comorbidities, Osteoporosis and Fractures in Ankylosing Spondylitis:  a Systematic Literature Review

Carmen Stolwijk1, A.M. Van Tubergen2, Jose Dionisio Castillo-Ortiz3 and Annelies Boonen4, 1Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 2Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, 3Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, 4Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Comorbidity and spondylarthropathy

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Comorbidities, both related and unrelated to the concept of spondyloarthritis (SpA), are common in patients with ankylosing spondylitis (AS) and may have substantial influence on health outcomes. However, data on the prevalence of these comorbidities in AS vary substantially. Objective of the study was to review the literature on the prevalence of SpA-related comorbidities uveitis, psoriasis and inflammatory bowel disease (IBD), as well as on prevalence of osteoporosis and vertebral fractures in patients with AS.

Methods: Medline, Embase and Cochrane were searched systematically up to November 2011, supplemented by a hand search of references. Specific MeSH headings and key words were used to identify all relevant studies without restriction of languages. Articles were eligible if reporting original data on the prevalence of one of the above mentioned comorbidities in studies on adult patients with AS. Study quality was assessed independently by 2 authors using a predefined criteria list. Demographic and prevalence data were extracted and studies were combined to express prevalence with 95% confidence intervals (CI) weighted for the number of patients included in the studies.

Results: Out of 7817 studies initially retrieved, 188 met the inclusion criteria. Additionally, 13 studies were found by hand search. The prevalence of uveitis, psoriasis, IBD, osteoporosis and vertebral fractures could be calculated in respectively 137 (40141 patients), 53 (25695 patients), 66 (30410 patients), 24 (2786 patients), and 17 articles (2285 patients). The overall (weighted) mean age was 43.9 (SD 6.9) years, mean disease duration 16.7 (SD 6.2) years and 63.7% were men. The weighted prevalence of uveitis was 30.3% (95% CI 30.2-30.4) for a mean disease duration of 16.4 (SD 6.4) years but increased with longer disease duration (from 19.4% for a disease duration of <10 years to 36.5% for a duration of >20 years). Prevalence of uveitis was also higher for studies using self-report compared to medical records (39.2% vs. 27.4%, p<0.001). Weighted prevalence of psoriasis was 11.3% (95% CI 11.2-11.4) for a mean disease duration of 18.0 (SD 6.3) years and prevalence of IBD was 7.2% (95% CI 7.1-7.2) for a mean disease duration of 17.8 (SD 6.4) years, without a clear relation to disease duration for both comorbidities. Prevalence of osteoporosis was 20.5% (19.4-21.6) in the lumbar spine, 10.9% (10.4-11.4) at the femoral neck and 29.2% (28.2-30.1) at both anatomical sites for a mean disease duration of 12.4 (SD 5.2) years in studies that screened for radiological evidence. The overall prevalence of osteoporosis increased with longer disease duration. Osteoporosis was diagnosed in 3.4% according to medical records data (936 patients). Vertebral fractures were present on 21.8% (21.0-22.4) of the radiographs for a mean disease duration of 19.5 (SD 6.1) years, and prevalence was 5.8% in studies using self-report (1071 patients).

Conclusion: SpA-related comorbidities, osteoporosis and vertebral fractures are very common in patients with AS but may vary with disease duration and method of investigation. Given the high prevalence, attention for comorbidities in relation to outcome in AS is recommended.


Disclosure:

C. Stolwijk,
None;

A. M. Van Tubergen,
None;

J. D. Castillo-Ortiz,
None;

A. Boonen,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-spondyloarthritis-related-comorbidities-osteoporosis-and-fractures-in-ankylosing-spondylitis-a-systematic-literature-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology